Wedbush Securities Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Wedbush Securities Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $147,231 - $226,750	-18,450 Closed	0 $0
Q3 2020 Oct 20, 2020	SELL	$7.96 - $12.42 $30,056 - $46,897	-3,776 Reduced 16.99%	18,450 $150,000
Q2 2020 Jul 16, 2020	BUY	$5.4 - $13.37 $35,823 - $88,696	6,634 Added 42.55%	22,226 $213,000
Q1 2020 Apr 17, 2020	BUY	$4.91 - $14.7 $19,640 - $58,800	4,000 Added 34.51%	15,592 $106,000
Q4 2019 Jan 16, 2020	SELL	$9.77 - $15.66 $1,465 - $2,349	-150 Reduced 1.28%	11,592 $173,000
Q3 2019 Oct 17, 2019	SELL	$9.59 - $12.0 $5,274 - $6,600	-550 Reduced 4.47%	11,742 $120,000
Q2 2019 Aug 01, 2019	SELL	$9.54 - $14.96 $4,770 - $7,480	-500 Reduced 3.91%	12,292 $130,000
Q1 2019 Apr 17, 2019	BUY	$10.31 - $14.38 $131,885 - $183,948	12,792 New	12,792 $179,000
Q2 2018 Aug 03, 2018	SELL	$8.3 - $16.8 $160,605 - $325,080	-19,350 Closed	0 $0
Q1 2018 May 01, 2018	BUY	$8.1 - $16.0 $156,735 - $309,600	19,350 New	19,350 $191,000
Q4 2017 Feb 09, 2018	SELL	$10.5 - $14.15 $108,675 - $146,452	-10,350 Closed	0 $0
Q3 2017 Oct 31, 2017	BUY	$7.7 - $11.55 $79,695 - $119,542	10,350	10,350 $114,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Wedbush Securities Inc, based on Form 13F filings with the SEC.

Stay updated on Wedbush Securities Inc with notifications on news.